Model Number ESS305 |
Device Problems
Adverse Event Without Identified Device or Use Problem (2993); Insufficient Information (3190)
|
Patient Problem
Abdominal Pain (1685)
|
Event Date 02/02/2016 |
Event Type
Injury
|
Event Description
|
The below report was received by health authority ansm (reference number: (b)(4)) on 21-feb-2024.This spontaneous case was originally reported by a consumer and describes the occurrence of abdominal pain ("abdominal pain") in a 50 year-old female patient who had essure inserted for female sterilisation.Additional non-serious events are detailed below.There was no information on the patient's medical history or concurrent conditions.On (b)(6) 2016, the patient had essure inserted.On (b)(6) 2016, the day of essure insertion, she experienced abdominal pain (seriousness criterion intervention required), dizziness ("dizziness"), malaise ("malaise"), migraine ("migraines"), myalgia ("muscle pain"), tendon pain ("tendon pain"), fatigue ("chronic fatigue"), cognitive disorder (" cognitive disorders"), tinnitus ("tinnitus"), tremor ("tremors"), urinary tract disorder ("urinary disorder"), arthralgia ("joint pain"), neck pain ("neck pain"), back pain ("back pain") and visual impairment ("sight disorder").Essure was removed on (b)(6) 2023.The patient was treated with surgery (to remove essure ).At the time of the report, the abdominal pain, migraine, myalgia, tendon pain, fatigue, neck pain and back pain had not resolved.The outcomes for cognitive disorder, tinnitus, tremor, urinary tract disorder, arthralgia and visual impairment were unknown.The reporter considered abdominal pain, arthralgia, back pain, cognitive disorder, dizziness, fatigue, malaise, migraine, myalgia, neck pain, tendon pain, tinnitus, tremor, urinary tract disorder and visual impairment to be related to essure administration.The reporter commented: on sick leave since (b)(6) 2022 with several attempts to resume being inconclusive.Still very fatigued and in pain despite removal.Diagnostic results (normal ranges are provided in parenthesis if available): body weight was reported to be 53 kg.Based on the available information, a review of our complaint records and other relevant data will be conducted; any new and reportable information that becomes available from our investigation will be provided in a supplementary report.
|
|
Manufacturer Narrative
|
The below report was received by health authority ansm (reference number: (b)(4)) on 21-feb-2024.The most recent information was received on 28-feb-2024.This spontaneous case was originally reported by a consumer and describes the occurrence of abdominal pain ("abdominal pain") in a 50 year-old female patient who had essure inserted for permanent contraceptive tubal implant.Additional non-serious events are detailed below.There was no information on the patient's medical history or concurrent conditions.On (b)(6) 2016, the patient had essure inserted.On (b)(6) 2016, the day of essure insertion, she experienced abdominal pain (seriousness criterion intervention required), dizziness ("dizziness"), malaise ("malaise"), migraine ("migraines"), myalgia ("muscle pain"), tendon pain ("tendon pain"), fatigue ("chronic fatigue"), cognitive disorder (" cognitive disorders"), tinnitus ("tinnitus"), tremor ("tremors"), urinary tract disorder ("urinary disorder"), arthralgia ("joint pain"), neck pain ("neck pain"), back pain ("back pain") and visual impairment ("sight disorder").The patient was treated with surgery (to remove essure).Essure was removed on (b)(6) 2023.At the time of the report, the abdominal pain, migraine, myalgia, tendon pain, fatigue, neck pain and back pain had not resolved.The outcomes for cognitive disorder, tinnitus, tremor, urinary tract disorder, arthralgia and visual impairment were unknown.The reporter considered abdominal pain, arthralgia, back pain, cognitive disorder, dizziness, fatigue, malaise, migraine, myalgia, neck pain, tendon pain, tinnitus, tremor, urinary tract disorder and visual impairment to be related to essure administration.The reporter commented: on sick leave since (b)(6) 2022 with several attempts to resume being inconclusive.Still very fatigued and in pain despite removal.Diagnostic results (normal ranges are provided in parenthesis if available): body weight was reported to be 53 kg.Quality-safety evaluation of ptc: for essure: no defect could be confirmed by the manufacturer.All product batches have met the specifications regarding labeling, material, and process controls at time of release.Trend analyses of complaints are reviewed regularly, no signal was observed with regard to the reported complaint reason.The risk management file was reviewed and an update was not deemed required.A technical investigation of the complaint sample and batch record review could not be conducted, as no sample or batch number were available.The most recent follow-up information incorporated above includes data received on: 28-feb-2024: quality safety evaluation of ptc.Based on the available information, a review of our complaint records and other relevant data was conducted; any new and reportable information that becomes available from our investigation will be provided in a supplementary report.
|
|
Search Alerts/Recalls
|
|